Latest News on TYRA

Financial News Based On Company


Advertisement
Advertisement

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Price Target of $47.40

https://www.marketbeat.com/instant-alerts/consensus-tyra-biosciences-inc-nasdaq-tyra-stock-has-consensus-price-target-of-4740-2026-11-14/
Analysts maintain a "Moderate Buy" consensus for Tyra Biosciences (NASDAQ:TYRA) with an average one-year price target of $47.40, despite the company reporting a wider-than-expected quarterly loss of $0.74 per share. Shares opened below their 50-day and 200-day moving averages at $20.02, reflecting concerns over recent financial performance. Institutional investors hold a significant 84.14% of the company's stock.

How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/16/How_Tyra_Biosciences_Inc._TYRA_Affects_Rotational_Strategy_Timing_111426122602_1794633962.html
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA) through an AI-driven quantitative research approach, identifying weak near-term sentiment that could lead to bearish positioning. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, while also providing multi-timeframe signal analysis for support and resistance levels.

Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $45.78, Implies 132% Upside

https://www.tradingview.com/news/tradingview:6f9374f17944f:0-tyra-biosciences-inc-stock-12-month-price-target-cut-to-45-78-implies-132-upside/
Tyra Biosciences, Inc. (TYRA) has seen its average 12-month price target reduced from $47.45 to $45.78 by 9 analysts, with individual forecasts ranging from $27 to $59 per share. This updated target still suggests a substantial 132% potential upside based on the November 12 closing price. The consensus rating from 13 covering analysts remains a "Buy," with 12 Buy recommendations and 1 Hold.

How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story

https://sg.finance.yahoo.com/news/phase-2-cancer-trial-data-002328136.html
Tyra Biosciences reported a Q3 2026 net loss of US$51.1 million, but a recent financing round secured US$400 million, extending its cash runway through 2030. This extended funding, combined with promising early Phase 2 data for dabogratinib in bladder cancer, is reshaping the company's investment narrative by providing more time for clinical and regulatory execution across its programs. The focus now shifts to confirmatory data and Phase 3 trial design, with dilution and continued unprofitability remaining key risks.

Wedbush maintains Tyra Biosciences at Outperform, raises price target to $57 from $53

https://www.tradingview.com/news/tradingview:3697c73a3ef0e:0-wedbush-maintains-tyra-biosciences-at-outperform-raises-price-target-to-57-from-53/
Wedbush has reiterated its "Outperform" rating for Tyra Biosciences (TYRA) and increased its price target to $57 from $53. This new price target suggests a potential upside of 171.4% from the stock's closing price on November 10th. Investors can find more detailed analyst data and recommendations for Tyra Biosciences on TradingView's platform.
Advertisement

HC Wainwright & Co. maintains Tyra Biosciences at Buy, lowers price target to $27 from $29

https://www.tradingview.com/news/tradingview:c3c8a825a8267:0-hc-wainwright-co-maintains-tyra-biosciences-at-buy-lowers-price-target-to-27-from-29/
HC Wainwright & Co. has reiterated its "Buy" rating for Tyra Biosciences (TYRA) but reduced its price target from $29 to $27, a 6.9% decrease. This new target suggests a potential upside of 28.6% from the stock's closing price of $21 on November 10. The article encourages readers to explore more detailed analyst data and ratings for Tyra Biosciences.

Tyra Biosciences (NASDAQ:TYRA) Stock Breaks Below Fifty Day Moving Average After Earnings Miss

https://www.marketbeat.com/instant-alerts/price-tyra-biosciences-nasdaq-tyra-stock-breaks-below-fifty-day-moving-average-after-earnings-miss-2026-11-10/
Tyra Biosciences (NASDAQ:TYRA) stock dropped below its 50-day moving average after reporting a quarterly loss of $0.74 per share, missing analyst expectations of a $0.67 loss. Despite the earnings miss, analysts maintain a "Moderate Buy" consensus with an average price target of $47.20, although Oppenheimer lowered its target from $50 to $40. Institutional investors and hedge funds hold a significant 84.14% of the company's shares.

Tyra Biosciences, Inc. (TYRA) Misses Q3 EPS by 7c

https://www.streetinsider.com/Earnings/Tyra+Biosciences%2C+Inc.+%28TYRA%29+Misses+Q3+EPS+by+7c/27323626.html
Tyra Biosciences, Inc. (TYRA) reported a Q3 EPS of ($0.74), which was $0.07 worse than the analyst estimate of ($0.67). The article also notes the current stock price of TYRA at $21.00, showing a 5.83% decrease today. This information is key for investors tracking the company's financial performance.

TYRA: Tyra Biosciences Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/tyra-biosciences-inc-filed-sec-form-8-k-results-of-operations-6783048
Tyra Biosciences Inc. filed an SEC Form 8-K reporting its Q3 2026 results, showing a net loss of $51.1 million, an increase from $29.9 million a year prior, driven by higher R&D and G&A expenses. The company also announced a successful $400 million stock offering in September, bringing its cash and marketable securities to $700.5 million, which is expected to fund operations through 2030. Initial Phase 2 SURF302 data showed positive overall response rates, although the offering dilutes existing shareholders, and early results may not be predictive of later outcomes.

Form 8K Tyra Biosciences Inc For: 10 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-tyra-biosciences-inc-for-10-november-93CH-4971577
This article announces that Tyra Biosciences Inc. filed a Form 8K on November 10th. The brief notice from Investing.com highlights this corporate filing for the company. The stock symbol TYRA is mentioned with a -5.83% change.
Advertisement

Tyra Biosciences Reports $51.1 Million Third-Quarter Net Loss

https://www.quiverquant.com/news/Tyra+Biosciences+Reports+%2451.1+Million+Third-Quarter+Net+Loss
Tyra Biosciences (TYRA) reported a third-quarter 2026 net loss of $51.1 million, an increase from $29.9 million a year earlier, with a net loss per share of $0.74. The company concluded September with $700.5 million in cash and expects these resources to fund operations through 2030. Additionally, initial Phase 2 SURF302 results showed a 79% overall response rate, and the company anticipates more Phase 2 results and a Phase 3 study for dabogratinib in 2027.

Form 8K Tyra Biosciences Inc For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-tyra-biosciences-inc-for-10-november-93CH-4946543
This article reports that Tyra Biosciences Inc. filed a Form 8K on November 10. The filing is a standard disclosure document used by companies to notify investors of unscheduled material events or corporate changes. The article provides the company's stock symbol (TYRA) and its recent performance.

Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights

https://www.quantisnow.com/insight/tyra-biosciences-reports-third-quarter-2026-financial-results-and-recent-6783009
Tyra Biosciences reported its third quarter 2026 financial results, showing an increased net loss of $51.1 million. Despite this, the company highlighted initial Phase 2 SURF302 data for oral dabogratinib, which demonstrated a 79% overall response rate in bladder cancer. A recent $400 million financing round is expected to fund operations through 2030, supporting continued development of its dabogratinib program.

Tyra will meet investors in Boston and London; its London presentation will be webcast live.

https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-participate-in-upcoming-investor-wafuolbg1zow.html
Tyra Biosciences announced its participation in the Guggenheim and Jefferies healthcare investor conferences in November 2026. The company will hold one-on-one meetings in Boston on November 10 at Guggenheim’s conference, and a hybrid presentation and one-on-one investor meetings in London on November 16 at the Jefferies conference, with a live webcast available. This highlights Tyra's efforts to engage with investors and showcase its precision medicine pipeline.

Tyra Biosciences to Participate in Upcoming Investor Conferences

https://www.tradingview.com/news/prnewswire:24b4beb479419:0-tyra-biosciences-to-participate-in-upcoming-investor-conferences/
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced its participation in two upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference 2026 and the Jefferies Global Healthcare Conference in London. The company, a clinical-stage biotechnology firm, will discuss its next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. A live webcast of the Jefferies presentation will be available on their website for investors.
Advertisement

Behavioral Patterns of TYRA and Institutional Flows

https://news.stocktradersdaily.com/news_release/35/Behavioral_Patterns_of_TYRA_and_Institutional_Flows_110426124202_1793770922.html
An analysis of Tyra Biosciences Inc. (NASDAQ: TYRA) indicates a neutral near-term outlook with strong mid-term sentiment potentially stalling. The report highlights support being tested and an exceptional risk-reward setup targeting a 34.0% gain. Three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) are provided, tailored to different risk profiles and holding periods, along with multi-timeframe signal analysis.

Tyra Biosciences, Inc. (TYRA) Seasonal returns chart

https://uk.finance.yahoo.com/quote/TYRA/seasonality/
This article provides a seasonal returns chart for Tyra Biosciences, Inc. (TYRA), detailing the average monthly price return from 2021 to 2026. It includes current stock information, showing TYRA's real-time price on NasdaqGS. The page also features navigation to various financial data sections like news, statistics, historical data, and analysis.

Tyra Biosciences (TYRA) Set to Announce Quarterly Earnings on Wednesday

https://www.marketbeat.com/instant-alerts/upcoming-tyra-biosciences-tyra-set-to-announce-quarterly-earnings-on-wednesday-2026-10-28/
Tyra Biosciences (NASDAQ:TYRA) is expected to report its Q3 2026 earnings on Wednesday, November 4th, with analysts forecasting a loss of $0.6687 per share. The company previously missed estimates, reporting a $0.69-per-share loss. TYRA shares opened at $21.52, and the company has an average "Moderate Buy" rating with an average price target of $47.20 from analysts.

BlackRock amends its passive ownership disclosure in Tyra Biosciences (TYRA).

https://www.stocktitan.net/sec-filings/TYRA/schedule-13g-a-tyra-biosciences-inc-amended-passive-investment-disclo-55fa2a501931.html
BlackRock, Inc. has filed an amended Schedule 13G/A, disclosing a 4.8% beneficial ownership stake in Tyra Biosciences, Inc. (TYRA). The filing indicates BlackRock holds sole voting power over 3,243,666 shares and sole dispositive power over 3,304,658 shares. This amendment reflects the holdings of certain BlackRock business units, excluding others.

Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59

https://news.futunn.com/en/post/1002274293/barclays-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains
Barclays has reiterated its 'Buy' rating for TYRA Biosciences, Inc. (TYRA.US), maintaining a target price of $59. This indicates a continued positive outlook on the company's stock performance from the financial institution.
Advertisement

Tyra Biosciences, Inc. Estimates – NASDAQ:TYRA

https://www.tradingview.com/symbols/NASDAQ-TYRA/financials-estimates/
This article provides an overview of Tyra Biosciences, Inc. (NASDAQ: TYRA) financial estimates on TradingView. It highlights that users can explore reported financial data and analyst estimates across various statements, compare actual results with average, high, and low estimates, and visualize trends over time for income, balance sheet, and cash flow.

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Average Target Price of $47.20 According to Analysts

https://www.marketbeat.com/instant-alerts/consensus-tyra-biosciences-inc-nasdaq-tyra-stock-has-average-target-price-of-4720-according-to-analysts-2026-10-20/
Tyra Biosciences (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $47.20. The company's stock opened at $19.34, significantly below this target, and institutional investors hold a substantial 84.14% of its shares. Recent analyst actions have shown mixed revisions to price targets, while Tyra Biosciences continues to develop TYRA-300 for FGFR3-driven cancers.

Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/TYRA/
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biotechnology company focused on developing precision medicines for fibroblast growth factor receptor (FGFR) biology. The company's stock is currently trading at $20.91, up 1.50%, with a market cap of $1.438 billion. Analysts have an average 1-year target estimate of $47.45 for TYRA, with Oppenheimer recently reiterating an "Outperform" rating despite lowering the price target from $50 to $40.

TYRA BIOSCIENCES, INC. | 4: Statement of changes in beneficial ownership of securities-Officer Harris Todd

https://www.moomoo.com/news/notice/308154193/statement-of-changes-in-beneficial-ownership-of-securities-officer-harris
This document, a Statement of changes in beneficial ownership of securities (Form 4), details transactions related to Officer Harris Todd at TYRA BIOSCIENCES, INC. These filings are mandatory for insiders to report their stock transactions, indicating changes in their holdings of company securities.

TYRA BIOSCIENCES, INC. | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P. - moomoo

https://www.moomoo.com/news/notice/308153151/statement-of-changes-in-beneficial-ownership-of-securities-director-ra
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for TYRA BIOSCIENCES, INC. It reports changes in security ownership for RA CAPITAL MANAGEMENT, L.P., identified as a Director of the company. The document itself is not provided, only its classification.
Advertisement

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

https://finance.yahoo.com/markets/stocks/articles/tyra-biosciences-tyra-stock-looks-071111841.html
Tyra Biosciences stock has seen a 31.8% gain over the past three years, but its current market price appears expensive when compared to its book value. Trading at 3.6x book value, which is double the biotech industry average, suggests investors are paying a premium for its net assets. The company is still loss-making, making book value a critical metric for investors to consider.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tyra-biosciences-inc---tyra-302909628.html
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences, Inc. (TYRA) on behalf of investors. This investigation follows a significant drop in Tyra's stock price after the company released initial results from its Phase 2 study of dabogratinib, which, despite a favorable safety profile, reported Grade 3 adverse events in some participants. Investors who suffered losses are encouraged to contact the firm for more information regarding a potential class action lawsuit.

Avoiding Lag: Real-Time Signals in (TYRA) Movement

https://news.stocktradersdaily.com/news_release/10/Avoiding_Lag:_Real-Time_Signals_in_TYRA_Movement_101426034802_1792007282.html
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near and mid-term sentiment but a positive long-term outlook. It provides AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

https://ca.finance.yahoo.com/news/heres-why-tyra-biosciences-tyra-123502206.html
Tyra Biosciences (TYRA) has experienced a 27% stock price drop in the last four weeks, but indicators suggest a potential turnaround. The stock is currently in oversold territory according to its Relative Strength Index (RSI) of 29.84, and analysts have raised earnings estimates for the current year. Furthermore, TYRA holds a Zacks Rank #2 (Buy), indicating strong potential for near-term price appreciation.

Law firm probes Tyra Biosciences over possible securities fraud after drug trial safety concerns.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-pemegang-saham-tyra-biosciences
Pomerantz LLP is investigating Tyra Biosciences and its executives for potential securities fraud following drug trial results for dabogratinib. Despite a favorable safety profile, serious adverse events caused Tyra's stock to drop nearly 18%. The investigation aims to determine if investors were misled about the drug's safety.
Advertisement

Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell

https://www.nasdaq.com/videos/tyra-biosciences-inc-rings-nasdaq-stock-market-opening-bell
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company specializing in precision medicines for FGFR biology, rang the Nasdaq Stock Market Opening Bell. Todd Harris, CEO, led the ceremony. The company's SNÅP platform is used to develop drugs like oral dabogratinib and TYRA-430 for various cancers and genetically defined conditions.

Tyra Biosciences, Inc. Rings the Opening Bell

https://www.nasdaq.com/events/tyra-biosciences-inc-rings-opening-bell
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company, rang the Opening Bell at Nasdaq MarketSite. The event celebrated their focus on developing next-generation precision medicines targeting FGFR biology through their SNÅP platform. Todd Harris, Chief Executive Officer, performed the bell-ringing honors.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tyra Biosciences, Inc. (TYRA) And Encourages Shareholders to Reach Out

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1220748
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Tyra Biosciences, Inc. (TYRA) following a significant drop in stock price. This occurred after the company announced initial Phase 2 study results for dabogratinib, which, despite a favorable safety profile, reported Grade 3 treatment-emergent adverse events in some participants. The firm is encouraging shareholders who purchased Tyra securities to assist in the investigation.

Tyra Biosciences (TYRA) Short Interest & Short Float | Updated Oct 2026

https://www.marketbeat.com/stocks/NASDAQ/TYRA/short-interest/
Tyra Biosciences (TYRA) reported a short interest of 9.41 million shares as of September 30, 2026, marking a 4.69% decrease from the prior period and representing 18.03% of its public float. The short interest ratio is 8.8 days to cover. The article provides detailed historical short interest data, competitor comparisons, and answers common questions about short selling TYRA.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tyra-biosciences-inc---tyra-302902160.html
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences, Inc. following a significant stock price drop. The investigation stems from an announcement on September 9, 2026, regarding initial results from Tyra's Phase 2 study for its drug dabogratinib, which, despite being described as having a favorable safety profile, reported Grade 3 treatment-emergent adverse events in a notable percentage of participants. This news led to Tyra's stock falling 17.66%, prompting the law firm to examine potential unlawful business practices by the company's officers and/or directors.
Advertisement

Raymond James reiterates Strong Buy on Tyra Biosciences stock

https://www.investing.com/news/analyst-ratings/raymond-james-reiterates-strong-buy-on-tyra-biosciences-stock-93CH-4933825
Raymond James has reiterated a Strong Buy rating and a $50.00 price target for Tyra Biosciences (NASDAQ:TYRA) after a fireside chat with the company's CEO, focusing on the potential of dabogratinib for non-muscle invasive bladder cancer. Despite the stock trading at $20.93 with some analysts suggesting it might be overvalued, the firm highlights positive Phase 2 data and projected revenue of $2 billion by 2035 for dabogratinib across multiple indications. The company also boasts a strong financial position with more cash than debt and a high current ratio.

Tyra Biosciences Inc (TYRA-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/TYRA/
This article provides an overview of Tyra Biosciences Inc. (TYRA-Q) stock, including its price data, recent news, and analyst opinions. The company is highlighted as a precision oncology firm developing therapies to combat tumor resistance, with its lead product candidate being TYRA-300. The news section features multiple recent analyst ratings and company announcements regarding clinical trial advancements and equity financing.

Raymond James reiterates Strong Buy on Tyra Biosciences stock By Investing.com

https://ca.investing.com/news/stock-market-news/raymond-james-reiterates-strong-buy-on-tyra-biosciences-stock-93CH-4867242
Raymond James has reiterated a Strong Buy rating and a $50.00 price target for Tyra Biosciences (NASDAQ: TYRA) following a discussion with the company's CEO. The firm highlighted the potential of its lead asset, dabogratinib, in treating non-muscle invasive bladder cancer and other conditions, projecting total combined revenue of $2 billion by 2035. Despite not yet being profitable, Tyra Biosciences maintains a strong financial position with more cash than debt and a robust current ratio.

Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history

https://au.finance.yahoo.com/quote/TYRA/
Tyra Biosciences, Inc. (TYRA) is a clinical-stage biotechnology company focused on developing precision medicines for fibroblast growth factor receptor (FGFR) biology. The company's stock was trading at $20.93, up 2.45% at market close on October 5, 2026, with a pre-market price of $19.90. TYRA has a market capitalization of $1.439 billion and its lead product candidates include FGFR3 for metastatic urothelial carcinoma and TYRA-300 for skeletal conditions.

Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/TYRA/
This Yahoo Finance page provides a comprehensive overview of Tyra Biosciences, Inc. (TYRA) stock, including its current price, historical data, performance metrics, and key financial information. It details the company's biotechnology focus on precision medicines for FGFR biology and highlights its lead product candidates and clinical trials. The article also includes analyst insights and performance comparisons against the S&P 500.
Advertisement

Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/TYRA/
Tyra Biosciences, Inc. (TYRA) stock closed at $20.43, down 2.76%, on October 2, 2026. The clinical-stage biotechnology company focuses on developing precision medicines for fibroblast growth factor receptor (FGFR) biology, with lead product candidates for various cancers and genetic conditions. Analysts have an average target price of $47.45 for TYRA, with a "Strong Buy" recommendation.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tyra-biosciences-inc---tyra-302895462.html
Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (NASDAQ: TYRA) following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices, particularly after the company announced initial Phase 2 study results for dabogratinib, which led to a 17.66% decline in stock value due to concerns about adverse events. Investors who suffered losses are encouraged to contact the law firm.

Will Phase 2 Safety Concerns Change Tyra Biosciences Stock Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/will-phase-2-safety-concerns-change-tyra-biosciences-stock-n
Tyra Biosciences is facing legal scrutiny from Bronstein, Gewirtz & Grossman, LLC due

Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59

https://www.moomoo.com/news/post/1000448502/barclays-maintains-tyra-biosciences-inc-tyraus-with-buy-rating-maintains
Barclays has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its target price at $59. This indicates a continued positive outlook on the company's stock performance by the firm.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

https://www.financialcontent.com/article/gnwcq-2026-9-29-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tyra-biosciences-inc-tyra
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences, Inc. (NASDAQ: TYRA) on behalf of investors. This investigation follows a 17.66% drop in Tyra's stock price on September 9, 2026, after the company announced initial results from its SURF302 Phase 2 study, which included reports of Grade 3 treatment-emergent adverse events in some participants. Investors are encouraged to contact the law firm for more information regarding the class action investigation.
Advertisement

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tyra Biosciences, Inc. (TYRA) and Encourages Shareholders to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1220747
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential claims against Tyra Biosciences, Inc. (TYRA) following a significant drop in its stock price. This drop occurred after Tyra released initial results from its SURF302 study, which, despite indicating a favorable safety profile, also reported Grade 3 treatment-emergent adverse events in some participants. The firm is encouraging investors who purchased Tyra securities to join the investigation.

Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/tyra-biosciences-inc.-tyra-investigation-bronstein-gewirtz-and-g-1220744
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Tyra Biosciences, Inc. (TYRA) following a significant stock price drop. The investigation stems from the release of initial Phase 2 study results for dabogratinib, which, despite a favorable safety profile, noted Grade 3 treatment-emergent adverse events in some participants, leading to a 17.66% decrease in Tyra's stock. Shareholders who purchased Tyra securities are encouraged to contact the firm to learn more and potentially assist with the investigation.

Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-349732-shares-of-tyra-biosciences-inc-tyra-2026-09-26/
Bank of America Corp DE has acquired 349,732 shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, valued at approximately $11.17 million, representing a 0.59% stake in the company. Institutional investors now collectively own 84.14% of Tyra Biosciences. Despite a recent stock decline, missing earnings estimates, and a "sell" rating from Weiss Ratings, analysts maintain a "Moderate Buy" consensus with an average target price of $46.89, expecting narrower losses in the future.

Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating

https://finance.yahoo.com/markets/stocks/articles/oppenheimer-adjusts-price-target-tyra-125014009.html
Oppenheimer has lowered its price target for Tyra Bioscience (TYRA) to $40 from $50, while maintaining an Outperform rating on the stock. Despite the adjustment, the biotech company still holds an average "buy" rating with a mean price target of $47.45 among analysts. This article is marked as premium content, requiring a subscription to view the full details.

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

https://www.marketbeat.com/instant-alerts/consensus-tyra-biosciences-inc-nasdaq-tyra-stock-has-consensus-target-price-of-4689-2026-09-25/
Tyra Biosciences (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fourteen research firms, with an average one-year price target of $46.89, significantly above its recent trading price of $22.41. While analysts like HC Wainwright have raised future EPS estimates due to expectations of narrower losses, others like Oppenheimer have lowered price targets, indicating mixed views. The clinical-stage biotechnology company remains unprofitable and its valuation is highly dependent on clinical progress, execution, and funding.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement